fda compounding glp-1 warning letters september 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of CDER Warning Letters Jump 50%

The endothelial glycocalyx: new diagnostic and therapeutic approaches in sepsis

This translated into an absolute risk reduction of about 0.69%

Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity

Ros required labs and video visit are a safety feature and also the reason onboarding is slow

found that semaglutide significantly reduced DPN-associated pain behaviors and neuroinflammation in STZ-induced diabetic rats [86]

Medicare (the federal program for those over 65) covers GLP-1 drugs for the treatment of type 2 diabetes and will probably cover their use for cardiovascular risk reduction in people with obesity/overweight